Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）

Generic Name: Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）

Indication: 用于：1.恶性肿瘤、白血病化、放疗引起的白血病减少及其并发的感染；

2.造血干/祖细胞移植后髓系造血功能受抑及延迟植活与移植排斥；

3.与rhG-CSF等造血生长因子联合或单独应用于外周血造血干/祖细胞移植前的干/祖细胞动员；

4.再生障碍性贫血等骨髓衰竭性疾患及各种严重感染并发的中性粒细胞减少；

5.也可用于艾滋病本身、或因药物治疗所致的中性粒细胞减少。

Clinical Trials

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

Phase 1

Not yet recruiting

Conditions: Multiple Myeloma
Relapse Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Drug: Elranatamab
Biological: GM-CSF
Biological: DC/MM Fusion Vaccine

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-25

Lead Sponsor: David Avigan

Target Recruit Count: 25

Registration Number: NCT06799026

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Tebentafusp-tebn With LDT in Metastatic UM

Phase 1

Not yet recruiting

Conditions: Metastatic Uveal Melanoma

Interventions: Drug: Tebentafusp-Tebn
Drug: GM-CSF (Sargramostim)
Drug: BCNU

First Posted Date: 2024-10-04

Last Posted Date: 2025-02-10

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 109

Registration Number: NCT06626516

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

The Effect of GM-CSF to Preventing Oral Mucositis for Patients With Nasopharyngeal Carcinoma Receiving Radiotherapy

Phase 2

Recruiting

Conditions: GM-CSF

Interventions: Drug: GM-CSF

First Posted Date: 2024-06-25

Last Posted Date: 2024-06-25

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 138

Registration Number: NCT06472739

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Phase 2

Recruiting

Conditions: Neuroblastoma

Interventions: Drug: Universal Donor (UD) TGFβi NK Cells
Drug: Temozolomide
Drug: Irinotecan
Drug: Dinutuximab
Drug: GM-CSF

First Posted Date: 2024-06-10

Last Posted Date: 2025-01-31

Lead Sponsor: New Approaches to Neuroblastoma Therapy Consortium

Target Recruit Count: 62

Registration Number: NCT06450041

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
UCSF Benioff Children's Hospital, San Francisco, California, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States

and more 10 locations

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Phase 2

Recruiting

Conditions: Neuroblastoma

Interventions: Drug: Naxitamab monotherapy
Drug: Irinotecan
Drug: Temozolomide
Drug: GM-CSF
Drug: Naxitamab in combination therapy
Drug: GM-CSF with combination regimen
Drug: Sintilimab

First Posted Date: 2023-08-28

Last Posted Date: 2023-09-21

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 30

Registration Number: NCT06013618

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Phase 2

Recruiting

Conditions: Advanced Solid Tumor
Refractory Tumor

Interventions: Drug: Thymalfasin
Radiation: Radiotherapy
Drug: PD-1/PD-L1 inhibitor
Drug: GM-CSF

First Posted Date: 2023-03-30

Last Posted Date: 2023-03-30

Lead Sponsor: Second Affiliated Hospital of Soochow University

Target Recruit Count: 60

Registration Number: NCT05790447

Locations: 🇨🇳
The Second Affiliated Hospital of SchoowUniversity, Suzhou, China

Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors

Phase 2

Recruiting

Conditions: Objective Response Rate

Interventions: Drug: GM-CSF

First Posted Date: 2023-03-08

Last Posted Date: 2023-03-08

Lead Sponsor: Xiangpan Li

Target Recruit Count: 56

Registration Number: NCT05760196

Locations: 🇨🇳
Renmin Hospital of Wuhan University, Wuhan, Hubei, China

Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)

Phase 2

Not yet recruiting

Conditions: Carcinoma Breast
Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Vinorelbine
Radiation: Radiotherapy
Drug: PD-1/PD-L1 inhibitor
Drug: GM-CSF
Drug: IL-2

First Posted Date: 2022-11-02

Last Posted Date: 2022-11-02

Lead Sponsor: Second Affiliated Hospital of Soochow University

Target Recruit Count: 45

Registration Number: NCT05603013

Locations: 🇨🇳
Second Affiliated Hospital of Soochow University, Suzhou, China

PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.

Phase 2

Not yet recruiting

Conditions: Metastatic Solid Tumor

Interventions: Radiation: Hypofractionated radiotherapy
Drug: PD-L1 inhibitor
Drug: GM-CSF
Drug: IL-2

First Posted Date: 2022-09-07

Last Posted Date: 2022-09-07

Lead Sponsor: Second Affiliated Hospital of Soochow University

Target Recruit Count: 56

Registration Number: NCT05530200

ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab

Phase 2

Not yet recruiting

Conditions: Glioma, Malignant

Interventions: Drug: ERC1671
Drug: GM-CSF
Drug: Cyclophosphamide
Drug: Pembrolizumab

First Posted Date: 2022-05-09

Last Posted Date: 2022-05-13

Lead Sponsor: Epitopoietic Research Corporation

Target Recruit Count: 28

Registration Number: NCT05366062

Locations: 🇹🇭
Bumrungrad International Hospital, Bangkok, Vadhana, Thailand

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy